Treatment Patterns and Clinical Outcomes Among Chinese Patients With Newly Diagnosed Multiple Myeloma: A Multicenter Retrospective Study (CHAMP‐MM)
ABSTRACT The therapeutic landscape for newly diagnosed multiple myeloma (NDMM) in China has evolved significantly with wider access to novel agents, including proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and CD38 monoclonal antibodies. However, real‐world data on treatment patterns and outcomes, particu...